Comments on the Debate Over Whether Lecanemab Should Be Extended Beyond 18 Months
By
Springer Healthcare IME
FEATURING
Zvezdan Pirtošek
By
Springer Healthcare IME
FEATURING
Zvezdan Pirtošek
Comments on the debate over whether lecanemab should be extended beyond 18 months
This video is part of the Independent Medical Education program entitled "Journey to a New Era for Alzheimer's Disease". The much-anticipated era of disease-modifying therapy for Alzheimer’s disease has at last dawned, promising significant changes in how the condition is perceived and managed.
Guide yourself through this transition with our carefully designed independent Alzheimer’s disease education program, led by world renowned experts and covering the biggest international conferences and disclosures across 2024.
This program is available in English, French, Spanish, Italian, German, Japanese and Simplified Chinese. Register in your preferred language before you start.
To learn more about the full program, visit https://new-era-alzheimers-disease.ime.springerhealthcare.com/.
This activity is supported by an educational grant from Lilly.
This video is part of the Independent Medical Education program entitled "Journey to a New Era for Alzheimer's Disease". The much-anticipated era of disease-modifying therapy for Alzheimer’s disease has at last dawned, promising significant changes in how the condition is perceived and managed.
Guide yourself through this transition with our carefully designed independent Alzheimer’s disease education program, led by world renowned experts and covering the biggest international conferences and disclosures across 2024.
This program is available in English, French, Spanish, Italian, German, Japanese and Simplified Chinese. Register in your preferred language before you start.
To learn more about the full program, visit https://new-era-alzheimers-disease.ime.springerhealthcare.com/.
This activity is supported by an educational grant from Lilly.
Comments 0
Login to view comments.
Click here to Login
